June 6th 2016, Beijing, China 

“A novel anticancer agent SNG1153 inhibits growth of lung cancer stem/progenitor cells” is published online on Oncotarget (IF 6.4) on Jun 2nd, 2016. (Link: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=9783&author-preview=7jr). Drs. Shiyang Liu and Yuming Guo from Shenogen are co-first authors in this study.

Lung cancer is the leading cause of cancer-related death in both men and women. Lung cancer contains a small population of cancer cells with stem-like features known as cancer stem cells (CSCs). CSCs are often more resistant to current therapeutic treatments. Thus, it is urgent to develop a novel agent that is able to inhibit CSCs growth. In this study, we examined the ability of SNG1153, a novel chemical agent derived from Icaritin to inhibit the growth of lung CSCs. We found that SNG1153 inhibited growth and induced apoptosis in established lung cancer cells. We also found that SNG1153 inhibited the tumorsphere formation and decreased CD133-positive (lung CSC marker) cancer cells. SNG1153 was able to attenuate tumor formation in NOD/SCID (non-obese diabetic/ severe combined immunodeficient) mice injected with lung tumorsphere cells. We further demonstrated that SNG1153 induced β-catenin phosphorylation and down-regulated β-catenin. Our results thus demonstrate that SNG1153 effectively inhibits the growth of lung CSCs and suggest that SNG1153 may be a novel therapeutic agent to treat human lung cancer.


The “Oncotarget” paper published by Drs. Guo and Liu from Shenogen introduced SNG1153 recent MOA progress on lung cancer therapy